Clinical Pharmacokinetics
Cure8 research brief
Why This Matters
Vedolizumab blood levels can vary with disease activity; a model that links intestinal α4β7 expression to drug exposure helps explain why some patients have lower drug levels and may need different dosing. This could inform personalized dosing strategies to improve treatment response in UC and Crohn’s disease.
Who Should Pay Attention
Clinicians treating adults with moderate-to-severe UC or Crohn’s disease, researchers developing PK/PD models or precision‑dosing approaches, and patients on vedolizumab or interested in biologic drug monitoring.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthMetadata only
What To Know
This open‑access Clinical Pharmacokinetics article reports a physiologically based pharmacokinetic (PBPK) model for vedolizumab that incorporates target‑mediated drug disposition (TMDD) and disease‑dependent α4β7 expression.
The authors parameterized and verified the model against clinical pharmacokinetic data, then simulated how increased target abundance in active IBD can raise clearance and lower systemic exposure — sometimes producing trough concentrations below suggested efficacy thresholds.
The paper frames the model as a tool to support model‑informed precision dosing for adults with UC and CD.
Keep In Mind
This article is a model‑building clinical pharmacokinetics study (open access) that uses published data and simulations; it does not present new randomized trial results or direct clinical dosing recommendations. Model predictions (including thresholds cited) should be interpreted as hypothesis‑generating and would require clinical validation before changing practice.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationClinical Pharmacokinetics
PublisherSpringer Science and Business Media LLC
AuthorsSanjana Parikh, Kei Irie, Ryota Tanaka +3 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 27, 2026, 12:00 AM
Content availableMetadata only
Funding disclosed by the source: National Institute of Diabetes and Digestive and Kidney Diseases, award DK132408; Japan Research Foundation for Clinical Pharmacology
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Real-world patterns of inflammatory bowel disease treatment across adult and pediatric populations: a nationwide cohort study in South Korea
Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...
Current and novel biomarkers for predicting and assessing therapeutic response in inflammatory bowel disease: a systematic review.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Highlights of the 2026 European Crohn's and Colitis Conference: redefining the IBD care continuum.
ECCO 2026 presented multiple studies that could change IBD care across prevention, medical therapy (including pediatric data), complication‑directed strategies (perianal fistula), and technology‑assisted monitoring....